Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT-11 in ulcerative colitis
NCT03861143Phase 2Completed
- Sponsor
- NImmune Biopharma
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of omilancor in ulcerative colitis (UC) (3 arms), sponsored by NImmune Biopharma. Primary endpoint: Clinical Remission at 12 weeks. Started Aug 2019; status: completed.
02
Drugs
omilancor
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03861143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861143.